<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 21, 2000
------------------
InKine Pharmaceutical Company, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
New York 0-24972 13-3754005
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
1720 Walton Road, Suite 200, Blue Bell, Pennsylvania 19422
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 260-9350
--------------
<PAGE>
Item 5. Other Events
On September 21, 2000, the Company issued a Press Release (See Exhibit
99.1 to this Form 8-K) announcing that the Company received notification from
the United States Food and Drug Administration ("FDA") that Visicol(TM) tablets
(brand of sodium phosphate) for cleansing of the bowel as a preparation for
colonoscopy was approved for marketing. The approval occurred within ten months
from the NDA submission and included full labeling of the product as agreed to
by the FDA and the Company. The Company has projected January 2001 as the date
on which it intends to make Visicol(TM) available to patients undergoing
colonoscopy.
Item 7. Exhibits
The following exhibits are filed as part of this report on Form 8-K:
Exhibit No. Title
----------- -----
99.1 Press Release, dated September 21, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
INKINE PHARMACEUTICAL COMPANY, INC.
By: /s/ Robert F. Apple
---------------------------------
Robert F. Apple
Senior Vice President and Chief Financial Officer
Dated: September 28, 2000
-2-
<PAGE>
EXHIBIT INDEX
Exhibit No. Title
----------- -----
99.1 Press Release, dated September 21, 2000.
